DOCSLIB.ORG

14Th Congress of the European Forum for Research in Rehabilitation (EFRR)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
14Th Congress of the European Forum for Research in Rehabilitation (EFRR) Parallel Session 6.3 - Family / Carer / Peer Involvement 14th Congress of the European Forum for Research in Rehabilitation (EFRR) Glasgow Caledonian University Glasgow, Scotland, UK 24 - 27 May 2017 Conference Information Conference Information Index 01 Welcome to the 14th EFRR Congress in Glasgow 03 Committees and Support 04 Programme Overview Welcome 07 Glasgow Caledonian University to the 14th Congress of the European • How to get there Forum for Research in Rehabilitation • Campus Map 2017 in Glasgow! 09 Congress Information A-Z We would like to cordially invite you to take part in the 11 Other useful information 14th Congress of the European Forum for Research in • Continuing Professional Development (CPD) Rehabilitation, to be held in Glasgow, UK, from 24-27 Accreditation May 2017. • Awards • EFRR Conference Hotel Information This meeting is intended to provide everyone involved in rehabilitation research, practice, education, technology Scientifi c Programme: Abstracts and policy making with an excellent opportunity to share cutting-edge research and best practice, and strengthen their 13 Wednesday 24th May networks in the vibrant city of Glasgow, UK. • Workshops The theme of this conference is “Working in partnership 15 Thursday 25th May across boundaries”, which refl ects the EFRR’s endeavour to • Plenary Sessions and Oral Presentations improve the lives of people with disabilities and their families • Poster Sessions (p.36) through the advancement of research and education in all biopsychosocial aspects of rehabilitation. 71 Friday 26th May EFRR 2017 will be hosted jointly by the Society for Research • Plenary Sessions and Oral Presentations This requires working together across multiple boundaries, in Rehabilitation (SRR) www.srr.org.uk and the British • Poster Sessions (p.96) fostering strong and strategic collaborations between Society of Rehabilitation Medicine (BSRM) www.bsrm.org. research, clinical practice and industry, di§ erent clinical- uk who have a long and successful track record of hosting 129 Saturday 27th May academic disciplines and professional bodies, as well as conferences together. health and social care and non-governmental organisations. 131 Author Index We would like to take this opportunity to express our We are honoured and delighted to host the EFRR 2017 sincere thanks to the many colleagues, organisations and at Glasgow Caledonian University (GCU), in Glasgow, volunteers, who have so generously contributed their time United Kingdom. As a modern university with brand new and expertise, making this congress a reality. We hope that conference facilities, conveniently located within the city the 14th Congress of the EFRR 2017 will be an inspiring event mindmaze logotype 12 - 02 - 2015 centre, GCU looks forward to welcoming you. with excellent networking opportunities for junior as well as established colleagues. Aarne Ylinen Frederike van Wijck With Scotland being the host country, delegates will be EFRR President Conference Chair, EFRR Vice- guarenteed a distinctive Scottish touch to the meeting. The Welcome to the EFRR in Glasgow! President and SRR Senior Secretary European Forum for Research in Rehabilitation Merz Pharma UK Ltd MindMaze Healthcare UK PAL Technologies Ltd Sponsors Brain Injury Rehabilitation Trust The Huntercombe Group 260 Centennial Park, Elstree Hill South, G19 The Perfume Factory, 50 Richmond Street, Glasgow, G1 1XP 3 Westgate Court, Silkwood Park, Murdostoun Brain Injury and Neurological Care Elstree, Herts, WD6 3SR 140 Wales Farm Road, London, W3 6UG T: +44 141 303 8380 Wakefi eld, WF5 9TJ Centre, Bonkle, Wishaw, Lanarkshire, ML2 9BY T: +44 (0)208 236 0000 T: +44 20 3051 2888 E: [email protected] T: +44 1924 266344 E: [email protected] Kay Forbes, Head of Therapy T: +44 (0) 7766087169 E: [email protected] E: uk.o [email protected] www.birt.co.uk [email protected] [email protected] www.paltechnologies.com www.huntercombe.com 01 Congress of the European Forum for Research in Rehabilitation (EFRR). Glasgow Caledonian University 02 Conference Information Conference Information EFRR 2017 Committees and support EFRR 2017 Programme Overview: Organising Committee Senior Advisory Committee BSRM Executive Committee Whole Congress • Frederike van Wijck, Conference Chair, • Hermie Hermens, • Diane Playford, President EFRR Vice-President and SRR Senior Secretary • Tracey Howe, • Krystyna Walton, President-Elect • Audrey Bowen, SRR President • John Hunter, • Lynne Turner-Stokes, Immediate Past Wednesday Thursday Friday Saturday • Philippa Dall, Senior Research Fellow, • Garth Johnson, President Glasgow Caledonian University • Lajos Kullmann, • Eliezar Okirie, Honorary Secretary 24 May 25 May 26 May 27 May • Patricia Dziunka, SRR Central Secretariat • Crt Marincek. • Lloyd Bradley, Deputy Honorary Secretary 09.00 07.30 08.00 09.00 - 09.45 • Nigel Harris, SRR and EFRR Past Secretary • Mike Barnes, Treasurer Registration opens Registration opens Registration opens Plenary 5: • Stefan Heiskanen, EFRR Member, • Judith Allanson, Elected Member/Chair Hamish Wood Building, Prof Matilde Leonardi Treasurer Trauma Rehabilitation Special Interest Group GCU, Main entrance 08.30 - 09.15 08.30 - 09.15 EFRR Council Welcome and Opening Plenary 3: 09.45 - 10.30 • Ben Stansfield, Reader, Glasgow • Fahim Anwar, Elected Caledonian University • Aarne Ylinen, President 13.30 Prof Frederike van Wijck, Mrs. Kate Allatt Expert Panel Discussion: • Bhaskar Basu, Elected Welcome Tea/ Coee Dr John Hunter OBE Prof Frederike van Wijck (Chair) • Sandy Weatherhead, BSRM Executive • Frederike van Wijck, Vice-President & Prof Aarne Ylinen 09.20 - 10.20 Director • John Burn, Co-optee - European • Gülseren Akyüz, Past President representative 14.00-17.00 Parallel Sessions: 4.1, 4.2, 4.3 10.30 - 11.15 • Aarne Ylinen, EFRR President. • Susanne Weinbrenner, Secretary (including break from 15.15 - 15.55) 09.20 - 10.20 Coee/Tea, Exhibition, Posters • Mahesh Cirasanambati, Ex-ocio - Workshop 1: Parallel Sessions: 1.1, 1.2, 1.3 10.20 - 11.00 • Helena Burger, EFRR Council Member Chair, Musculoskeletal Special Interest Group Chronic Pain Syndromes Coee/Tea, Exhibition, Posters 11.15 - 11.45 • Gabor Fazekas, Member • Lorraine Graham, Ex-ocio - Chair, Prof Gülseren Akyüz & Dr Esra 10.20 - 11.00 What’s new and where to next? Scientific Committee • Sven-Uno Marnetoft, Member Special Interest Group for Amputee Medicine Giray Coee/Tea, Exhibition, Posters 11.00 - 12.15 Dr. Andrew Bateman Parallel Sessions: 5.1, 5.2, 5.3 • Frederike van Wijck, Conference Chair, • Matilde Leonardi, Member • Naveen Kumar, Ex-ocio - Chair, Spinal EFRR Vice-President and SRR Senior Secretary Cord Medicine Special Interest Group Workshop 2: 11.00 - 12.15 11.45 - 12.00 • Aivars Vetra, Member Priority Setting Partnerships Parallel Sessions: 2.1, 2.2, 2.3 12.15 - 13.45 Awards & Closing Remarks: • Gülseren Akyüz, EFRR Past President • Emer McGilloway, Ex-ocio - Chair, • Stefan Heiskanen, Treasurer. Dr. Alex Pollock Lunch, Exhibition, Posters Prof Frederike van Wijck 2013-2015 Vocational Rehabilitation Special Interest 12.15 - 13.45 EFRR AGM • Stephen Ashford, SRR Junior Secretary Group Workshop 3: Lunch, Exhibition, Posters 12.00 • Andrew Bateman, SRR President Elect • Meenakshi Nayar/Rebekah Implementing Evidence-Based SRR AGM 13.45 - 14.30 Conference Closes Practice: Plenary 4: • Audrey Bowen, SRR President SRR Council Davidson, Ex-ocio - National Trainee Representatives Prof Marion Walker MBE 13.45 - 14.30 Dr. Sven-Uno Marnetoft • Helena Burger, EFRR Council Member • Audrey Bowen, President & Dr Rebecca Fisher Plenary 1: • Margaret Phillips, Ex-ocio - Chair, • Gabor Fazekas, EFRR Past President • Chris Burton, Past President Prof Peter Langhorne 14.35 - 15.35 Research & Clinical Standards Sub-Committee 17.00 - 18.30 Parallel Sessions: 6.1, 6.2, 6.3 (2008-2009, 2011-2013) and Council • Andrew Bateman, President Elect & Academic A§airs Sub-committee Member Social Event: 14.35 - 15.35 • Frederike van Wijck, Senior Secretary • Naweed Sattar, Elected Member Wecome Reception Parallel Sessions: 3.1, 3.2, 3.3 15.35 - 16.15 • Joanna Fletcher-Smith, SRR Council • Anand Pandyan, Past Secretary Coee/Tea, Exhibition, Posters member • Manoj Sivan, Elected Member • Stephen Ashford, Junior Secretary 15.35 - 16.15 • Karen Homan, SRR Public Relations • Matthew Smith, Elected Member Coee/Tea, Exhibition, Posters 16.15 - 17.00 Ocer • Lisa Shaw, Treasurer • Elizabeth Stoppard, Ex-ocio - Chair, Parallel Sessions: 7.1, 7.2, 7.3 • Rosie Kneafsey, SRR Council member • Karen Homan, Public Relations Ocer Education Sub-committee 16.15 - 17.00 Plenary 2: • Praveen Kumar, SRR Council member • Joanna Fletcher-Smith, Member • Krystyna Walton, President-Elect and Ex- ocio as Chair, RCP Joint Specialty Committee Prof Gülseren Akyüz • Matilde Leonardi, EFRR Council Member • Praveen Kumar, Member • Sachin Watve, Elected Member. • Sven-Uno Marnetoft, EFRR Council • Diane Playford, BSRM President. 18.30 - 23.00 Member Social Event: Glasgow City Chambers Civic • Anand Pandyan, SRR Past Secretary Reception • Diane Playford, BSRM President EFRR 2017 Professional • Kate Radford, SRR Past President Congress Organiser • Lisa Shaw, SRR Treasurer • Abbey • Manoj Sivan, BSRM Executive Committee www.abbeyconference.ie/home Member • Aivars Vetra, EFRR Past President (2009- 2011) and Council Member Additional Congress Support • Tony Ward, BSRM member and • Glasgow Caledonian University representative on SRR Council Events Management Team: • Susanne Weinbrenner, EFRR Secretary Julie
Load more

Recommended publications
  • Rare Variant Contribution to Human Disease in 281,104 UK Biobank Exomes W ­ 1,19 1,19 2,19 2 2 Quanli Wang , Ryan S
    https://doi.org/10.1038/s41586-021-03855-y Accelerated Article Preview Rare variant contribution to human disease W in 281,104 UK Biobank exomes E VI Received: 3 November 2020 Quanli Wang, Ryan S. Dhindsa, Keren Carss, Andrew R. Harper, Abhishek N ag­­, I oa nn a Tachmazidou, Dimitrios Vitsios, Sri V. V. Deevi, Alex Mackay, EDaniel Muthas, Accepted: 28 July 2021 Michael Hühn, Sue Monkley, Henric O ls so n , S eb astian Wasilewski, Katherine R. Smith, Accelerated Article Preview Published Ruth March, Adam Platt, Carolina Haefliger & Slavé PetrovskiR online 10 August 2021 P Cite this article as: Wang, Q. et al. Rare variant This is a PDF fle of a peer-reviewed paper that has been accepted for publication. contribution to human disease in 281,104 UK Biobank exomes. Nature https:// Although unedited, the content has been subjectedE to preliminary formatting. Nature doi.org/10.1038/s41586-021-03855-y (2021). is providing this early version of the typeset paper as a service to our authors and Open access readers. The text and fgures will undergoL copyediting and a proof review before the paper is published in its fnal form. Please note that during the production process errors may be discovered which Ccould afect the content, and all legal disclaimers apply. TI R A D E T A R E L E C C A Nature | www.nature.com Article Rare variant contribution to human disease in 281,104 UK Biobank exomes W 1,19 1,19 2,19 2 2 https://doi.org/10.1038/s41586-021-03855-y Quanli Wang , Ryan S.
    [Show full text]
  • The ELIXIR Core Data Resources: ​Fundamental Infrastructure for The
    Supplementary Data: The ELIXIR Core Data Resources: fundamental infrastructure ​ for the life sciences The “Supporting Material” referred to within this Supplementary Data can be found in the Supporting.Material.CDR.infrastructure file, DOI: 10.5281/zenodo.2625247 (https://zenodo.org/record/2625247). ​ ​ Figure 1. Scale of the Core Data Resources Table S1. Data from which Figure 1 is derived: Year 2013 2014 2015 2016 2017 Data entries 765881651 997794559 1726529931 1853429002 2715599247 Monthly user/IP addresses 1700660 2109586 2413724 2502617 2867265 FTEs 270 292.65 295.65 289.7 311.2 Figure 1 includes data from the following Core Data Resources: ArrayExpress, BRENDA, CATH, ChEBI, ChEMBL, EGA, ENA, Ensembl, Ensembl Genomes, EuropePMC, HPA, IntAct /MINT , InterPro, PDBe, PRIDE, SILVA, STRING, UniProt ● Note that Ensembl’s compute infrastructure physically relocated in 2016, so “Users/IP address” data are not available for that year. In this case, the 2015 numbers were rolled forward to 2016. ● Note that STRING makes only minor releases in 2014 and 2016, in that the interactions are re-computed, but the number of “Data entries” remains unchanged. The major releases that change the number of “Data entries” happened in 2013 and 2015. So, for “Data entries” , the number for 2013 was rolled forward to 2014, and the number for 2015 was rolled forward to 2016. The ELIXIR Core Data Resources: fundamental infrastructure for the life sciences ​ 1 Figure 2: Usage of Core Data Resources in research The following steps were taken: 1. API calls were run on open access full text articles in Europe PMC to identify articles that ​ ​ mention Core Data Resource by name or include specific data record accession numbers.
    [Show full text]
  • Open Targets Genetics
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.16.299271; this version posted September 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 Open Targets Genetics: An open approach to systematically prioritize causal variants 2 and genes at all published GWAS trait-associated loci 3 4 Edward Mountjoy1,2, Ellen M. Schmidt1,2, Miguel Carmona2,3, Gareth Peat2,3, Alfredo Miranda2,3, 5 Luca Fumis2,3, James Hayhurst2,3, Annalisa Buniello2,3, Jeremy Schwartzentruber1,2,3, Mohd 6 Anisul Karim1,2, Daniel Wright1,2, Andrew Hercules2,3, Eliseo Papa4, Eric Fauman5, Jeffrey C. 7 Barrett1,2, John A. Todd6, David Ochoa2,3, Ian Dunham1,2,3, Maya Ghoussaini1,2,*. 8 9 1. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 10 1SA, UK 11 2. Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK 12 3. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), 13 Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK 14 4. Systems Biology, Biogen, Cambridge, MA, 02142, United States 15 5. Integrative Biology, Internal Medicine Research Unit, Pfizer Worldwide Research, 16 Development and Medical, Cambridge, MA 02139, United States 17 6. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford 18 Biomedical Research Centre, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, 19 UK 20 * Corresponding author 21 22 23 24 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.16.299271; this version posted September 17, 2020.
    [Show full text]
  • Select Committee on Science and Technology Corrected Oral Evidence: Ageing: Science, Technology and Healthy Living
    Select Committee on Science and Technology Corrected oral evidence: Ageing: science, technology and healthy living Tuesday 25 February 2020 10.20 am Watch the meeting Members present: Lord Patel (The Chair); Lord Borwick; Lord Browne of Ladyton; Baroness Hilton of Eggardon; Lord Kakkar; Lord Mair; Baroness Manningham-Buller; Baroness Penn; Viscount Ridley; Baroness Rock; Baroness Sheehan; Baroness Walmsley; Lord Winston; Baroness Young of Old Scone. Evidence Session No. 15 Heard in Public Questions 131 - 138 Witnesses Dame Fiona Caldicott, National Data Guardian; Matthew Gould, CEO, NHSX; Chris Roebuck, Chief Statistician, NHS Digital; Dr Jem Rashbass, Executive Director of Master Registries and Data, NHS Digital. USE OF THE TRANSCRIPT This is a corrected transcript of evidence taken in public and webcast on www.parliamentlive.tv. 1 Examination of witnesses Dame Fiona Caldicott, Matthew Gould, Chris Roebuck and Dr Jem Rashbass. Q131 The Chair: Good morning, Dame Fiona and gentlemen. Welcome and thank you for coming today to help us with this inquiry. There are some familiar faces to me; it is nice to see you. Before we start, would you mind introducing yourselves for the record from my left? If you want to make an opening statement, feel free to do so. If you have any interests to declare, please do so at the beginning. Chris Roebuck: I am the chief statistician at NHS Digital. I am accountable for the nearly 300 sets of official statistics we produce each year. These cover a range of health and care data, predominantly in England, including administrative data, clinical data and survey data. We release them to encourage transparency, to help with local and national decision-making and for public accountability.
    [Show full text]
  • Annual Scientific Report 2013 on the Cover Structure 3Fof in the Protein Data Bank, Determined by Laponogov, I
    EMBL-European Bioinformatics Institute Annual Scientific Report 2013 On the cover Structure 3fof in the Protein Data Bank, determined by Laponogov, I. et al. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nature Structural & Molecular Biology 16, 667-669. © 2014 European Molecular Biology Laboratory This publication was produced by the External Relations team at the European Bioinformatics Institute (EMBL-EBI) A digital version of the brochure can be found at www.ebi.ac.uk/about/brochures For more information about EMBL-EBI please contact: [email protected] Contents Introduction & overview 3 Services 8 Genes, genomes and variation 8 Molecular atlas 12 Proteins and protein families 14 Molecular and cellular structures 18 Chemical biology 20 Molecular systems 22 Cross-domain tools and resources 24 Research 26 Support 32 ELIXIR 36 Facts and figures 38 Funding & resource allocation 38 Growth of core resources 40 Collaborations 42 Our staff in 2013 44 Scientific advisory committees 46 Major database collaborations 50 Publications 52 Organisation of EMBL-EBI leadership 61 2013 EMBL-EBI Annual Scientific Report 1 Foreword Welcome to EMBL-EBI’s 2013 Annual Scientific Report. Here we look back on our major achievements during the year, reflecting on the delivery of our world-class services, research, training, industry collaboration and European coordination of life-science data. The past year has been one full of exciting changes, both scientifically and organisationally. We unveiled a new website that helps users explore our resources more seamlessly, saw the publication of ground-breaking work in data storage and synthetic biology, joined the global alliance for global health, built important new relationships with our partners in industry and celebrated the launch of ELIXIR.
    [Show full text]
  • Core Outcome Measures for Interventions to Prevent Or Slow the Progress of Dementia for People Living with Mild to Moderate Deme
    RESEARCH ARTICLE Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations Lucy Webster1, Derek Groskreutz2, Anna Grinbergs-Saull3, Rob Howard1, John a1111111111 T. O'Brien4, Gail Mountain5, Sube Banerjee6, Bob Woods7, Robert Perneczky8,9,10, a1111111111 Louise Lafortune11, Charlotte Roberts12, Jenny McCleery13, James Pickett3, a1111111111 Frances Bunn14, David Challis15, Georgina Charlesworth16, Katie Featherstone17, a1111111111 Chris Fox18, Claire Goodman14, Roy Jones19, Sarah Lamb20, Esme Moniz-Cook21, a1111111111 Justine Schneider22, Sasha Shepperd23, Claire Surr24, Jo Thompson-Coon25, Clive Ballard26, Carol Brayne11, Alistair Burns27, Linda Clare25,28, Peter Garrard29, Patrick Kehoe30, Peter Passmore31, Clive Holmes32, Ian Maidment33, Louise Robinson34, Gill Livingston1,35,36* 1 Division of Psychiatry, University College London, London, United Kingdom, 2 Division of Psychology and OPEN ACCESS Language Sciences, University College London, London, United Kingdom, 3 Alzheimer's Society, London, United Kingdom, 4 Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom, Citation: Webster L, Groskreutz D, Grinbergs-Saull 5 ScHARR, University of Sheffield, Sheffield, United Kingdom, 6 Centre for Dementia Studies, Brighton and A, Howard R, O'Brien JT, Mountain G, et al. (2017) Sussex Medical School, Brighton, United Kingdom, 7 Dementia Services Development Centre Wales, Core outcome measures for
    [Show full text]
  • Genome-Wide Rare Variant Analysis for Thousands of Phenotypes in Over 70,000 Exomes from Two Cohorts
    ARTICLE https://doi.org/10.1038/s41467-020-14288-y OPEN Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts Elizabeth T. Cirulli 1*, Simon White 1, Robert W. Read 2,3, Gai Elhanan2,3, William J. Metcalf2,3, Francisco Tanudjaja 1, Donna M. Fath1, Efren Sandoval1, Magnus Isaksson1, Karen A. Schlauch2,3, Joseph J. Grzymski2,3, James T. Lu1 & Nicole L. Washington1 1234567890():,; Understanding the impact of rare variants is essential to understanding human health. We analyze rare (MAF < 0.1%) variants against 4264 phenotypes in 49,960 exome-sequenced individuals from the UK Biobank and 1934 phenotypes (1821 overlapping with UK Biobank) in 21,866 members of the Healthy Nevada Project (HNP) cohort who underwent Exome + sequencing at Helix. After using our rare-variant-tailored methodology to reduce test statistic inflation, we identify 64 statistically significant gene-based associations in our meta-analysis of the two cohorts and 37 for phenotypes available in only one cohort. Singletons make significant contributions to our results, and the vast majority of the associations could not have been identified with a genotyping chip. Our results are available for interactive browsing in a webapp (https://ukb.research.helix.com). This comprehensive analysis illustrates the biological value of large, deeply phenotyped cohorts of unselected populations coupled with NGS data. 1 Helix, 101S Ellsworth Ave Suite 350, San Mateo, CA 94401, USA. 2 Desert Research Institute, 2215 Raggio Pkwy, Reno, NV 89512, USA. 3 Renown Institute of Health Innovation, Reno, NV 89512, USA. *email: [email protected] NATURE COMMUNICATIONS | (2020) 11:542 | https://doi.org/10.1038/s41467-020-14288-y | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14288-y ver the past decade, we have witnessed the growing depth HNP cohort.
    [Show full text]
  • Wellcome Trust Annual Report and Financial Statements 2019 Is © the Wellcome Trust and Is Licensed Under Creative Commons Attribution 2.0 UK
    Annual Report and Financial Statements 2019 Table of contents Report from Chair 3 Report from Director 5 Trustee’s Report 7 What we do 8 Review of Charitable Activities 9 Review of Investment Activities 21 Financial Review 31 Structure and Governance 36 Social Responsibility 40 Risk Management 42 Remuneration Report 44 Remuneration Committee Report 46 Nomination Committee Report 47 Investment Committee Report 48 Audit and Risk Committee Report 49 Independent Auditor’s Report 52 Financial Statements 61 Consolidated Statement of Financial Activities 62 Consolidated Balance Sheet 63 Statement of Financial Activities of the Trust 64 Balance Sheet of the Trust 65 Consolidated Cash Flow Statement 66 Notes to the Financial Statements 67 Alternative Performance Measures and Key Performance Indicators 114 Glossary of Terms 115 Reference and Administrative Details 116 Table of Contents Wellcome Trust Annual Report 2019 | 2 Report from Chair During my tenure at Wellcome, which ends in The macro environment is increasingly challenging, 2020, I count myself lucky to have had the which has created volatility in financial markets. opportunity to meet inspiring people from a rich Q4 2018 was a very difficult quarter, but the diversity of sectors, backgrounds, specialisms resumption of interest rate cuts by the US Federal and scientific fields. Reserve underpinned another year of gains for our portfolio. We recognise that the cycle is extended, Wellcome’s achievements belong to the people and that the portfolio is likely to face more who work here and to the people we fund – it is challenging times ahead. a partnership that continues to grow stronger, more influential and more ambitious, spurred by The team is working hard to ensure that our independence.
    [Show full text]
  • UK Biobank: a Model for Public Engagement?
    Genomics, Society and Policy 2005, Vol.1, No.3, Comment, pp.78–81. UK Biobank: a model for public engagement? MAIRI LEVITT Whilst in other applications of genetic technology the public debate has begun only when a piece of research has been completed, public consultations on biobanking began in 2000, before the funding for UK Biobank was even agreed, and have continued throughout its development. UK Biobank has obvious attractions for the British public. It is being set up specifically as a resource for research into common diseases that are relevant to everyone, rather than rare genetic disorders unknown to most. The only diseases mentioned on the ‘about UK Biobank’ web page are cancer, heart disease, diabetes and Alzheimer’s disease1. The public are encouraged to be involved by the promise of ‘a better life for our children and grandchildren’ and ‘enormous potential to result in improvements to health of the UK population’ through the National Health Service.2 Ensuring public support Despite these selling points it was recognised by the Medical Research Council (MRC) and Wellcome Trust from the start, that work would have to be done to ensure that UK Biobank would be a success3. The early consultations indicated reasons why public support could not be taken for granted. There was recognition of a problem of trust in science and science governance in the UK with the ‘BSE crisis’ and the media furore over GM food following the reporting of Pusztai’s research with rats and GM potatoes and his concerns over GM food4. The first public consultation on UK Biobank stated that genetic research had ‘a raft of unhelpful negative associations, based sometimes on misinformation and mistaken assumptions’5 In contrast ‘some people were better informed…and tended to have a more favourable view’ 6.
    [Show full text]
  • Wellcome Trust Finance Plc (Incorporated in England and Wales Under the Companies Act 1985 with Registered Number 5857955) £275,000,000 4.75 Per Cent
    Wellcome Trust Finance plc (incorporated in England and Wales under the Companies Act 1985 with registered number 5857955) £275,000,000 4.75 per cent. Guaranteed Bonds due 2021 guaranteed (as described herein) by Wellcome Trust (a charity registered under the Charities Act 1993 with registered number 210183) Issue Price 98.902 per cent The £275,000,000 4.75 per cent. Guaranteed Bonds due 2021 (the “Bonds”) will be issued by Wellcome Trust Finance plc (the “Issuer”). The payment of all amounts due in respect of the Bonds will be unconditionally and irrevocably guaranteed pursuant to the terms of a guarantee (the “Guarantee”) given by The Wellcome Trust Limited (in its capacity as trustee of the Wellcome Trust). Interest on the Bonds is payable annually in arrear on 28 May in each year. Payments on the Bonds will be made without withholding or deduction for or on account of taxes of the United Kingdom to the extent described under “Terms and Conditions of the Bonds – Taxation”. The Bonds will mature on 28 May 2021 but may be redeemed before that date at the option of the Issuer in whole but not in part at any time at a redemption price which is equal to the higher of (i) their principal amount and (ii) a price calculated by reference to the yield on the relevant United Kingdom government stock, plus 0.10 per cent., in each case, together with accrued interest. See “Terms and Conditions of the Bonds – Redemption and Purchase”. The Bonds are also subject to redemption in whole but not in part, at their principal amount, together with accrued interest, at the option of the Issuer at any time in the event of certain changes affecting taxes of the United Kingdom.
    [Show full text]
  • Alcohol Consumption in the General Population Is Associated With
    RESEARCH ARTICLE Alcohol consumption in the general population is associated with structural changes in multiple organ systems Evangelos Evangelou1,2, Hideaki Suzuki3,4,5†, Wenjia Bai5,6†, Raha Pazoki7,8, He Gao1,7, Paul M Matthews5,9,10, Paul Elliott1,7,9,10,11* 1Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom; 2Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece; 3Department of Cardiovascular Medicine, Tohoku University Hospital, Sendai, Japan; 4Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan; 5Department of Brain Sciences, Imperial College London, London, United Kingdom; 6Data Science Institute, Imperial College London, London, United Kingdom; 7MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom; 8Division of Biomedical Sciences, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, London, United Kingdom; 9UK Dementia Research Institute at Imperial College London, London, United Kingdom; 10National Institute for Health Research Imperial College Biomedical Research Centre, Imperial College London, London, United Kingdom; 11British Heart Foundation Centre for Research Excellence, Imperial College London, London, United Kingdom Abstract *For correspondence: Background: Excessive alcohol consumption is associated with damage to various organs, but its [email protected] multi-organ effects have not been characterised across the usual range of alcohol drinking in a †These authors contributed large general population sample. equally to this work Methods: We assessed global effect sizes of alcohol consumption on quantitative magnetic resonance imaging phenotypic measures of the brain, heart, aorta, and liver of UK Biobank Competing interest: See participants who reported drinking alcohol.
    [Show full text]
  • Processes in Recruitment to Randomised Controlled Trials of Medicines for Children (RECRUIT): a Qualitative Study
    Health Technology Assessment 2011; Vol. 15: No.151 Summary Health Technology Assessment 2011; Vol. 15: No. 15 ISSN 1366-5278 ISSN 1366-5278 Chapter 5 AbstractDiscussion Summary of main findings ListStrengths of abbreviations and limitations Comparison with existing evidence: what does this study add? ExecutiveImplications summary RecommendationsBackground for research Objectives AcknowledgementsMethods ContributionResults of authors Conclusions Processes in recruitment to randomised ReferencesImplications ResearchRecommendations protocol for research controlled trials of medicines for Funding Health Technology Assessment programme children (RECRUIT): a qualitative study Chapter 1 Introduction Background Parents V Shilling, PR Williamson, H Hickey, E Sowden, Young people Practitioners RL Smyth and B Young Rationale and objectives Chapter 2 Methods Sampling of trials and sites Procedure for recorded trial discussions Procedure for interviews Analysis Sampling of trial discussions, families and practitioners and participant characteristics Changes to protocol Other clarifications and changes to the methodology Chapter 3 Analysis strand 1: communication about trials as observed and experienced Summary of objectives Communication as observed Communication as experienced Participant information leaflets Impact of relationships on the trial approach Parents’ and young people’s suggestions for improving the trial approach Summary Chapter 4 Analysis strand 2: what influenced decision-making? Summary of objectives What is important to parents when being approached about trials? March 2011 Saying ‘no’ to a trial 10.3310/hta15150 Being ineligible for a trial The role of practitioners in parents’ decisions Trust in medical research Changing views of research Young people Health Technology Assessment NIHR HTA programme www.hta.ac.uk HTA How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk).
    [Show full text]